Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · IEX Real-Time Price · USD
21.21
-0.21 (-0.98%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Hims & Hers Health Revenue
Hims & Hers Health had revenue of $959.40M in the twelve months ending March 31, 2024, with 55.65% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $278.17M with 45.81% year-over-year growth. In the year 2023, Hims & Hers Health had annual revenue of $872.00M with 65.49% growth.
Revenue (ttm)
$959.40M
Revenue Growth
+55.65%
P/S Ratio
4.56
Revenue / Employee
$917,209
Employees
1,046
Market Cap
4.38B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 872.00M | 345.08M | 65.49% |
Dec 31, 2022 | 526.92M | 255.04M | 93.81% |
Dec 31, 2021 | 271.88M | 123.12M | 82.77% |
Dec 31, 2020 | 148.76M | 66.20M | 80.18% |
Dec 31, 2019 | 82.56M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coca-Cola FEMSA | 14.45B |
Darling Ingredients | 6.42B |
Flowers Foods | 5.13B |
The Boston Beer Company | 2.02B |
Lancaster Colony | 1.87B |
Primo Water | 1.68B |
Inter Parfums | 1.33B |
The Simply Good Foods Company | 1.28B |
HIMS News
- 1 day ago - Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier' - Fast Company
- 6 weeks ago - Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy - Fox Business
- 6 weeks ago - Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages - Fast Company
- 6 weeks ago - Hims & Hers Health Stock Jumps Nearly 28% on Plans to Offer GLP-1 Weight-Loss Drugs - Investopedia
- 6 weeks ago - Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy - Forbes
- 6 weeks ago - Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings - Market Watch
- 6 weeks ago - The case for the overvalued Hims & Hers stock - Invezz
- 6 weeks ago - Hims & Hers Health adds compounded GLP-1 injections to weight loss program - CNBC